Results 61 to 70 of about 20,292 (247)

Perbandingan Risiko Kardiovaskuler Menggunakan Metode Framingham, WHO Chart dan ASCVD Pada Pekerja PT. X Tahun 2021: Comparison of Cardiovascular Risk Using the Framingham Method, WHO Chart and ASCVD in PT. X Year 2021

, 2022
Latar Belakang: Penyakit kardiovaskular (CVD) adalah penyebab kematian nomor satu secara global, dan identifikasi lebih dini terhadap risiko tinggi sangat penting untuk mencegah penyakit CVD dan mengurangi biaya perawatan kesehatan.
null Anharudin, null Mila Tejamaya, Mila Tejamaya, Anharudin   +3 more
core   +1 more source

Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli‐D Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare the efficacy and safety of the fixed‐ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with premixed insulin degludec plus insulin aspart (IDegAsp) according to the injection time of IDegAsp. Materials and Methods The 24‐week, multicentre, randomised, open‐label Soli‐D study enrolled Chinese adults ...
Xin Li, Juan Wang, Tong Liu, Agustina Alvarez, Felipe Lauand, Lydie Melas‐Melt, Lei Kang, Qin Du, Ming Liu   +8 more
wiley   +1 more source

Proteomic Profiling Captures Residual Cardiovascular Risk Beyond the PREVENT Model in Individuals With Cardiovascular–Kidney–Metabolic Syndrome Stages 2–3

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Cardiovascular–kidney–metabolic (CKM) syndrome reflects complex pathobiological interactions among metabolic disorders, kidney injury, and cardiovascular disease (CVD). Stages 2 and 3 represent critical phases of disease progression characterised by high pathological heterogeneity.
Xuefei Han, Jiacheng Ding, Jingqian Li, Yiyin Gao, Yunqian Li   +4 more
wiley   +1 more source

Cardio-ankle vascular index represents the best surrogate for 10-year ASCVD risk estimation in patients with primary hypertension

, 2021
Background: Identification of target organ damage and/or risk-enhancing factors help treatment decisions in hypertensive and hyperlipidaemic patients who reside in borderline to an intermediate risk category based on 10-year atherosclerotic ...
Mustafa Tarik Agac, Süret Ağaç, Muhammed Necati Murat Aksoy, Mehmet Bülent Vatan   +3 more
core   +1 more source

Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Elevated lipoprotein(a) [Lp(a)] is a genetic ASCVD risk factor that often persists despite intensive LDL‐C lowering. We compared the efficacy and safety of emerging Lp(a)‐targeted therapies (siRNAs, antisense oligonucleotides and an oral assembly inhibitor) with PCSK9‐directed therapies.
Jihad Abu Zayed, Nada A. Al‐Awamleh, Mahmoud Hamad, Mohammad Ibrahim Mahmoud Hdaib, Hazem Ayesh   +4 more
wiley   +1 more source

The Risk of Atherosclerotic Cardiovascular Disease among Hyperlipidaemia Patients and Appropriateness of Statin Therapy

Pharmacology and Clinical Pharmacy Research, 2018
Patients with hyperlipidaemia is at increased risk of developing atherosclerotic cardiovascular disease (ASCVD). The use of appropriate statin therapy is important to obtain optimal health outcomes.
Maharani F. Iskandar, Nurmainah Nurmainah, Ressi Susanti   +2 more
doaj   +1 more source

Determinants of incident atherosclerotic cardiovascular disease events among individuals with type 2 diabetic microvascular complications in the UK: a prospective cohort study

Diabetology & Metabolic Syndrome, 2023
Objective To evaluate the association of atherosclerotic cardiovascular disease (ASCVD) risk factors with incident ASCVD events among type 2 diabetes (T2D) individuals with microvascular complications.
Yaxin Wang, Gabriella Bulloch, Yu Huang, Yingying Liang, Zijing Du, Guanrong Wu, Ying Fang, Yijun Hu, Xianwen Shang, Zhuoting Zhu, Xiayin Zhang, Xiaohong Yang, Honghua Yu   +12 more
doaj   +1 more source

Long-Term Outcomes Associated with NAFLD, ASCVD, and All-Cause Mortality of Patients with Metabolic Syndrome

, 2022
Metabolic syndrome (MetS) patients are at higher risk for nonalcoholic fatty liver disease (NAFLD), atherosclerotic cardiovascular diseases (ASCVD), and death.
Charatcharoenwitthaya, Phunchai, Ariyakunaphan, Pinyapat, Phisalprapa, Pochamana, Naruemit Sayabovorn, Punyisa Boonchai, Chaiwat Washirasaksiri, Washirasaksiri, Chaiwat, Phunchai Charatcharoenwitthaya, Sitasuwan, Tullaya, Pochamana Phisalprapa, Srivanichakorn, Weerachai, Thanet Chaisathaphol, Kositamongkol, Chayanis, Chonticha Auesomwang, Mepramoon, Euarat, Weerachai Srivanichakorn, Suchanart Jitrukthai, Jitrukthai, Suchanart, Pinyapat Ariyakunaphan, Tullaya Sitasuwan, Euarat Mepramoon, Nimitpunya, Pongpol, Auesomwang, Chonticha, Chayanis Kositamongkol, Chaisathaphol, Thanet, Pongpol Nimitpunya, Boonchai, Punyisa, Tinmanee, Rungsima, Sayabovorn, Naruemit, Rungsima Tinmanee   +29 more
core   +1 more source

Prediction of incident heart failure in type 2 diabetes mellitus: Rationale and design of the DM‐HEART study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Preclinical heart failure (HF) (stages A and B) is common but easily overlooked in asymptomatic patients with type 2 diabetes (T2D). There is a paucity of evidence regarding how coexisting risk factors contribute to the development of HF in asymptomatic Asian patients with T2D, and there is a lack of guidance on the early identification of ...
Jiun‐Lu Lin, Yen‐Wen Wu, Sung‐Chen Liu, Chung‐Ming Tu, Heng‐Hsu Lin, Yi‐Fu Lin, Hao‐Yun Chang, Ming‐Nan Chien, Chih‐Yuan Wang, Chung‐Lieh Hung   +9 more
wiley   +1 more source

ASCVD-free probability by level of continuity of care.

ASCVD = atherosclerotic cardiovascular disease. The group definitions are; HM = high COC with doctor; LM = low COC with doctor; HP = high COC with pharmacist; and LP = low COC with pharmacist.
Eunyoung Choi (23252), Juhee Lee (765246), Iyn-Hyang Lee (4860406), Eun Jin Jang (2591209), Eunjung Choo (9228027)   +4 more
core   +1 more source